NFE2L2 and polycystic ovary syndrome: I3C and linagliptin combination increased the SOD, CAT, Nrf2, and HO-1, decreased TGF-β, TNF-α, and IL-10, and reduced the plasma-free testosterone, luteinizing hormone, progesterone, and estradiol in PCOS, suggesting that I3C with linagliptin could be useful to treat PCOS by inhibiting inflammation and accelerating antioxidant levels [247].